Preoperative Metabolic Syndrome Is Predictive of Significant Gastric Cancer Mortality after Gastrectomy: The Fujian Prospective Investigation of Cancer (FIESTA) Study

详细信息    查看全文

• 作者：Dan Hu^a ; ¹ ; Feng Peng^b ; ¹ ; Xiandong Lin^a ; ¹ ; Gang Chen^a ; Hejun Zhang^a ; Binying Liang^c ; Kaida Ji^d ; Jinxiu Lin^b ; Lin-Feng Chen^e ; ^{lfchen@life.illinois.edu} ; Xiongwei Zheng^a ; ^{agu1960@126.com} ; Wenquan Niu^d ; ^{niuwenquan_shcn@163.com}
• 关键词：Gastric cancer ; Metabolic syndrome ; Prognosis ; Mortality ; Hyperglycemia
• 刊名：EBioMedicine
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：15
• 期：Complete
• 页码：73-80
• 全文大小：916 K
• 卷排序：15

文摘

We analyzed the impact of preoperative metabolic syndrome on the survival of 3012 gastric cancer patients after surgery over 15-year follow-up. This is by far the largest cohort study to evaluate the association between the preoperative metabolic syndrome and gastric cancer mortality. Preoperative metabolic syndrome, especially hyperglycemia, was predictive of significant gastric cancer mortality in patients after surgery.On the basis of 3012 patients with gastric cancer from the FIESTA study, we analyzed the impact of the preoperative MetS status on the survival of patients after radical gastrectomy over a period of 15-year follow-up. We found that preoperative MetS, especially hyperglycemia, was predictive of significant gastric cancer mortality in patients with radical gastrectomy, especially for early stage of gastric cancer. Pending its future validation in other large cohort studies, our findings could provide the basis for future personalized medicine, namely, gastric cancer patients with preoperative MetS should be identified early and treated with optimal regimens since these patients could have a poor survival probability.